How Does Retatrutide Work? Understanding GLP-1, GIP and Glucagon

Retatrutide is often described as a “triple-agonist” medication.

But what does that actually mean?

To understand how retatrutide works, we need to unpack the three hormonal pathways it targets:

• GLP-1

• GIP

• Glucagon

Together, these hormones regulate appetite, blood sugar, digestion and energy expenditure.

Retatrutide activates all three.

1️⃣ GLP-1: The Appetite Regulator

GLP-1 (glucagon-like peptide-1) is a hormone released in the gut after eating.

It:

• Signals fullness to the brain

• Slows gastric emptying

• Stimulates insulin release

• Reduces glucagon secretion

• Lowers blood glucose

This is the pathway targeted by semaglutide (Ozempic, Wegovy).

If you’re new to GLP-1 medications, read:
🧬 GLP-1 Effect on Nutrition (Ozempic, Mounjaro, Wegovy & Zepbound)

Slower gastric emptying is particularly important. It prolongs satiety but also changes digestive timing — something we’ll return to later.

2️⃣ GIP: The Metabolic Amplifier

GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after meals.

It:

• Enhances insulin secretion

• Influences fat metabolism

• May affect energy storage

• Works synergistically with GLP-1

Tirzepatide (Mounjaro, Zepbound) targets both GLP-1 and GIP.

The addition of GIP signalling appears to improve metabolic outcomes in some patients compared to GLP-1 alone.

3️⃣ Glucagon: The Energy Mobiliser

This is where retatrutide differs.

Glucagon is traditionally known as the “opposite” of insulin. It:

• Increases liver glucose production

• Mobilises stored energy

• Stimulates fat breakdown

• May increase energy expenditure

By activating glucagon receptors alongside GLP-1 and GIP, retatrutide may:

• Reduce appetite

• Increase calorie burn

• Alter substrate utilisation

This combination is why it’s sometimes called the “next-generation” obesity therapy.

Why Target All Three?

Weight regulation is complex.

Appetite control alone does not fully explain long-term metabolic adaptation. When calorie intake drops, the body often compensates by reducing energy expenditure.

By stimulating glucagon receptors, retatrutide may counter some of that adaptive slowdown.

In theory, this could mean:

• Greater weight reduction

• Sustained metabolic changes

• More pronounced appetite suppression

However, long-term data is still developing.

For a broader overview, see:
What Is Retatrutide? The Science Behind the “Triple-G” Injection

How Retatrutide Affects Digestion

Like other GLP-1–based medications, retatrutide slows gastric emptying.

That means:

• Food remains in the stomach longer

• Fullness lasts longer

• Meal frequency often decreases

While beneficial for appetite control, slower digestion can influence:

• Meal size

• Dietary variety

• Total micronutrient intake

To understand how digestion influences absorption, see:
How Do We Absorb Vitamins and Minerals?
Does Splitting Supplements Improve Absorption?

Does Triple Agonism Change Side Effects?

Early trial data suggests gastrointestinal symptoms similar to other GLP-1 medications, including:

• Nausea

• Reduced appetite

• Gastrointestinal discomfort

As doses increase, these effects may become more pronounced.

For a breakdown of common GLP-1 side effects, read:
Side Effects of Ozempic, Mounjaro & Other GLP-1 Injections in the UK

Retatrutide and Long-Term Metabolic Health

Because retatrutide influences multiple hormonal pathways, researchers are investigating potential effects on:

• Liver fat

• Insulin resistance

• Cardiometabolic markers

• Energy expenditure

It remains under clinical evaluation, and long-term safety profiles are still being established.

The Bigger Picture: Appetite vs Nutrition

All GLP-1–based medications share a common feature:

They reduce appetite.

Reduced appetite often means:

• Smaller meals

• Lower calorie intake

• Reduced dietary fat

• Lower protein intake

Over time, this can influence overall nutrient exposure.

For a deeper dive into nutritional implications, see:
Nutrient Deficiencies Common on GLP-1 Medications (Mounjaro, Ozempic, Wegovy, Zepbound)

FAQ: How Retatrutide Works

What makes retatrutide different from semaglutide?

Semaglutide targets GLP-1 only. Retatrutide activates GLP-1, GIP and glucagon receptors.

What does GIP do in weight loss medications?

GIP enhances insulin response and may improve metabolic signalling when combined with GLP-1.

Why is glucagon included in retatrutide?

Glucagon activation may increase energy expenditure and fat mobilisation, potentially enhancing weight loss effects.

Does retatrutide burn more calories?

Early research suggests glucagon receptor activity may increase energy expenditure, though long-term data is ongoing.

Does retatrutide slow digestion?

Yes, like other GLP-1–based medications, it slows gastric emptying.

If you’re wondering whether GLP-1 medications affect vitamin absorption, we examine the data in this guide.

Final Thoughts

Retatrutide represents a shift from single-hormone to multi-hormone targeting in obesity treatment.

By activating GLP-1, GIP and glucagon receptors simultaneously, it aims to influence appetite, metabolism and energy expenditure in a more integrated way.

As research continues, understanding both the metabolic and nutritional implications of triple-agonist therapy will be increasingly important.